There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous induction therapy in patients with moderately to severely active ulcerative colitis.

It is Colon Cancer Awareness Month. Intermountain Health wants everyone to know the importance of screenings and being aware that early detection saves lives. Screenings also has a profound impact ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Johnson & Johnson said that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative ...

The human gut is home to trillions of bacteria that play vital roles in digestion, immunity, and overall health.

Discover the 7 warning signs of ulcerative colitis, plus breakthrough treatments and management strategies that can transform ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

The recent approval of Omvoh for Crohn's disease marks the company's entry into the inflammation market, following the approval of Ebglyss for Atopic Dermatitis. These developments demonstrate Eli ...

Additionally, Eli Lilly is also making strides in other areas, like the recent approval of Omvoh for Crohn’s disease and the potential of Ebglyss for atopic dermatitis. These moves reflect Eli Lilly’s ...